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Background: Papua New Guinea (PNG) is a high tuberculosis (TB) burden country of the WHO Western Pacific
Region, but so far research on drug resistance (DR) and genotypes of Mycobacterium tuberculosis (M. tuberculosis)
was only conducted in few provinces in the country. The aim of the present study was to obtain baseline data on
the level of drug resistance and the genotypic diversity of circulating M. tuberculosis in additional provinces and to
investigate the differences between three selected sites across PNG.
Results: Genotyping of 147M. tuberculosis clinical isolates collected in Goroka, Eastern Highlands Province, in
Alotau, Milne Bay Province and in Madang, Madang Province revealed three main lineages of M. tuberculosis:
Lineage 4 (European-American lineage), Lineage 2 (East-Asian lineage) and Lineage 1 (Indo-Oceanic lineage). All
three lineages were detected in all three sites, but the individual lineage compositions varied significantly between
sites. In Madang Lineage 4 was the most prevalent lineage (76.6%), whereas in Goroka and Alotau Lineage 2 was
dominating (60.5% and 84.4%, respectively) (p < 0.001). Overall, phenotypic drug susceptibility testing showed 10.8%
resistance to at least one of the first-line drugs tested. Of all resistant strains (23/212) 30.4% were Streptomycin
mono-resistant, 17.4% were Isoniazid mono-resistant and 13% were Rifampicin mono-resistant. Multi-drug resistant
(MDR) TB was found in 2.8% of all tested cases (6/212). The highest amount of MDR TB was found in Alotau in
Milne Bay Province (4.6%).
Conclusion: A large number of drug resistant TB infections are present in the country and MDR TB has already
been detected in all three surveyed regions of PNG, highlighting the importance of monitoring drug resistance and
making it a high priority for the National Control Program. Due to the high prevalence of Lineage 2 in Milne Bay
Province and given the frequent association of this lineage with drug resistance, monitoring of the latter should
especially be scaled up in that province.
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Over the last decade, evidence for the impact of the bacter-
ial genetic background on TB infection and disease has
strongly increased [1]. A phylogeography ofM. tuberculosis
based on large sequence polymorphisms and confirmed by
multi-locus sequence analysis could furthermore be estab-
lished, showing an association between specific M. tuber-
culosis strains and a particular geographic region [2,3]. The
different M. tuberculosis strains were grouped into 6 main
lineages (a 7th was recently added [4]). Various studies
investigated the impact of different MTBC lineages on the
clinical presentation of the disease. Infection with Lineage
2 has for example been found to be associated with faster
progression to disease [5] and drug resistance [6,7]. Lineage
4 on the other hand, has been associated with pulmonary
TB rather than extrapulmonary TB [8]. In addition, few
studies have analysed the impact of the genetic background
of both, humans and bacteria on disease development [8,9]
and found correlations between different human genetic
polymorphisms with specific M. tuberculosis lineages.
However, findings from studies investigating lineage
specific associations have also reflected within lineage
variability [10,11]. Therefore, further discriminatory strain
differentiation methods should be considered when in-
vestigating M. tuberculosis genetic diversity. Nevertheless,
the various findings support the idea of a longstanding
host-pathogen co-evolution and the hypothesis that TB
spread together with the human out-of-Africa migration
[2,12,13]. To investigate the M. tuberculosis genetic diver-
sity within and between different populations could there-
fore give important insights into the dynamics of TB
disease and might help to inform national TB programs to
develop better control strategies.
Papua New Guinea (PNG) is a high TB burden country
with an estimated TB incidence rate of 348/100’000 in
2012 and its proportion of multidrug resistance (MDR) es-
timated at 4.9% in new cases is higher than the estimated
global average of 3.6% [14,15]. Publications on drug resist-
ant TB in PNG are rare, and previous data were mainly
derived from patients from Western Province, diagnosed
in Australia [16-19]. Gilpin et al. reported 25% MDR-TB
among patients from Western Province diagnosed be-
tween 2000 and 2006 [17]. Only two publications on DR
data from other provinces exist: Ballif et al. found that
5.2% of tested isolates of adult patients from Madang
were MDR-TB [20], and a recently published study from
Kikori in Gulf Province of PNG reported 9% of suspected
MDR-TB (based on Xpert® MTB/RIF) in the investigated
population [21].
PNG harbours a vast human genetic diversity and has
been isolated from the outside world for a long time. PNG
was populated through several waves of human migrations
and people living in the Highlands represent the oldest
population from the first migration wave about 50,000 yearsago [22,23]. The highlands region has only been ‘discov-
ered’ in the 1930s [24] and was sparsely populated at the
time. Hence it would be expected that evolutionary ‘an-
cient’ lineages of M. tuberculosis (e.g. Lineage 1 [25]), pro-
posed to be adapted to low density populations [26], would
be found there, whilst the ‘modern’ lineages such as
Lineage 2 and Lineage 4 would be expected at the highly
populated coastal regions. However, there is limited infor-
mation on the TB situation available in PNG. Since various
lineages have been found to differ in their prevalence be-
tween different regions of the same country (e.g. in
Indonesia [27] or Taiwan [28]) it is important to also iden-
tify the circulating strains in various communities in PNG.
To our knowledge, apart from a previous study conducted
in Madang province [29], another study where isolates
from patients from Western Province were analysed [17]
and a very recent study from Gulf Province [21], no other
data on the M. tuberculosis population structure from
PNG have been published.
The aim of the present study was to obtain baseline
data on the level of drug resistance and the genotypic di-
versity of circulating M. tuberculosis in selected sites of
three provinces of PNG (Goroka in Eastern Highlands
Province, Alotau in Milne Bay Province and Madang in




A total of 449 patients enrolled into our study were di-
agnosed with TB of any type. From 396 of these patients
sputum samples could be collected and of these 335
(74.6%) samples were available for study purposes (see
Figure 1). From 212 (63.3%) of the available samples M.
tuberculosis were successfully grown in culture and drug
susceptibility testing (DST) was performed. Details of
population characteristics per study site are described in
Table 1.
TB positivity peaked in the age group of 15 to 34 years,
which is consistent with country wide data [30]. And
79.1% (355/449) of patients clinically diagnosed with TB
had no history of the disease indicating ongoing trans-
mission. However, these data cannot be used to extrapo-
late for the whole country and further investigations are
required to analyse the transmission dynamics of the
disease in PNG.
Figure 1 depicts the flow of all isolates collected. Of
samples sent for culture 67.2% (225/335) could be recov-
ered showing a positive correlation between initial diag-
nostic bacterial count and culture success (likelihood
ratio χ2 = 140.6, df = 4, p < 0.001). The reduced culture
success might be likely due to the long distance trans-
port of samples between laboratories that was experi-
enced with samples from other studies.
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Figure 1 Flow chart of cohort sample size development from screening to genotyping.
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Genotyping of MTBC could successfully be conducted of
147/212 (69%) samples. With a TaqMan Real-time PCR
assay [31] three of seven worldwide reported MTBC line-
ages [3,12], were detected in all three study sites. Overall,
Lineage 4 was the most prevalent lineage with 75/147 iso-
lates (51.0%), followed by Lineage 2 with 67/147 isolates
(45.6%), whilst Lineage 1 was rare with 5/147 isolates
(3.4%). This composition of circulating lineages was similar
as previously described for Madang [29] and other parts of
PNG [17,21,32] and reflects the reduced MTBC diversity
within PNG compared to other countries of the region, e.g.Indonesia [27] or New Zealand [33] where Lineage 3 strains
were also found. When lineage compositions (shown in
Figure 2) were compared between the study sites, statisti-
cally significant differences were observed between all three
sites (Fisher’s exact test (p < 0.001)). Lineage 1 was generally
rare in all three sites. Lineage 4 was the most abundant
lineage in Madang (76.6%) similar to what has previously
been described [29]. In contrast, in Alotau Lineage 2 was
the dominant lineage (84.4%). In Goroka, a trend towards a
higher prevalence of Lineage 2 (60.5%) was found but was
not as high as in Alotau. However, it cannot be ruled out
that the low proportion of Lineage 1 in our cohort is due to
Table 1 Characteristics of study population for each study site
Drug susceptibility testing result available* Total TB positive (any type)
Characteristics Goroka n = 56 n (%) Alotau n = 66 n (%) Madang n = 90 n (%) Total n = 212 n (%) All sites n = 449 n(%)
Sex
Male 32 (57.1) 28 (42.4) 43 (47.8) 103 (48.6) 221 (49.22)
Female 24 (42.9) 38 (57.6) 47 (52.2) 109 (51.4) 228 (50.78)
Median age [IQR] 30 [25-40] 29 [24-42] 30 [24-40] 30 [24-40] 30 [25-42]
Age group
15-24: 13 (23.2) 19 (28.8) 27 (30.0) 59 (27.8) 110 (24.5)
25-34: 19 (33.9) 23 (34.9) 31 (34.4) 73 (34.4) 157 (35.0)
35-44: 12 (21.5) 9 (13.6) 16 (17.8) 37 (17.5) 76 (16.9)
45-54: 7 (12.5) 8 (12.1) 9 (10.0) 24 (11.3) 51 (11.4)
55-64: 4 (7.1) 4 (6.1) 5 (5.6) 13 (6.1) 40 (8.9)
>64: 0 2 (3.0) 1 (1.1) 3 (1.4) 11 (2.4)
missing: 1 (1.8) 1 (1.5) 1 (1.1) 3 (1.4) 4 (0.9)
Smear result
Smear positive 55 (98.2) 62 (93.9) 90 (100) 207 (97.6) 280 (62.4)
Smear negative 1 (1.8) 4 (6.1) 0 5 (2.4) 116 (25.8)
HIV
HIV+ 12 (21.4) 1 (1.5) 3 (3.3) 16 (7.5) 36 (8.0)
HIV- 23 (41.1) 12 (18.2) 43 (47.8) 78 (36.8) 140 (31.2)
HIV unknown 21 (37.5) 53 (80.3) 44 (48.9) 118 (55.7) 273 (60.8)
Region of origin
Highlands 25 (44.6) 0 3 (3.3) 28 (13.2) 71 (15.8)
Coast 4 (7.2) 23 (34.9) 84 (93.3) 111 (52.3) 171 (38.1)
Other country 0 0 1 (1.1) 1 (0.5) 1 (0.2)
Unknown 27 (48.2) 43 (65.1) 2 (2.2) 72 (34.0) 206 (45.9)
History of TB treatment
No 50 (89.3) 42 (63.6) 75 (83.3) 167 (78.8) 355 (79.1)
Yes 2 (3.6) 5 (7.6) 11 (12.2) 18 (8.5) 50 (11.4)
Unknown 4 (7.1) 19 (28.8) 4 (4.5) 27 (12.7) 44 (9.8)
*Data of 212 samples for which drug susceptibility was tested compared to 449 enrolled patients diagnosed with any type of TB. IQR = interquartile range.
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transmissibility [34] and a lower growth rate in macro-
phages compared to Lineage 2 and Lineage 4 [11] poten-
tially leading to a decreased culture recovery of Lineage 1.
We further performed spoligotyping, and the spoligotyp-
ing pattern with the corresponding families and frequen-
cies are shown in Figure 3. Thirty different spoligotyping
patterns belonged to nine different families, including 14
orphans with 12 different spoligotyping patterns. Orphans
were strains with no matching entry in the SITVIT data-
base and are therefore considered as undefined. Whether
these strains represent PNG specificM. tuberculosis strains
remains to be confirmed using other methods.
One of the Lineage 1 strains from Goroka exhibits a
special spoligotyping pattern with only spacers 40–43 be-
ing present (sample No. 4 in Figure 3). That spoligotypingpattern has been confirmed with in silico spoligotyping
using KvarQ [35]. Per standard definition, this would de-
fine that strain as belonging to the Beijing family of
Lineage 2 [36,37]. However, SNP-typing assigned this
strain to Lineage 1, therefore representing a ‘pseudo-
Beijing’ strain with convergent evolution leading to an in-
dependent deletion event in the direct repeat locus of
MTBC, similar to what has already been described for
strains of Lineage 3 [38].
All Lineage 4 samples belonging to the LAM spoligo-
typing family were exclusively found in Madang, also
reflecting the different M. tuberculosis lineage compos-
ition in the spoligotyping data. All Lineage 2 samples
belonged to the Beijing family and were subsequently
subtyped into three different monophyletic groups which
are sublineages defined by the presence or absence of
Figure 2 Mycobacterium tuberculosis lineage composition for each study site. Black bars = lineage 1 (Indo-Oceanic); dashed bars = lineage
2 (East-Asian); white bars = lineage 4 (Euro-American).
Figure 3 Spoligotypes for the observed lineages (n = 145). SIT = shared international type.
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http://www.biomedcentral.com/1471-2180/14/307specific regions of difference (RD) [36]. Over all three
sites, one sample of 67 Beijing strains belonged to subli-
neage 1, here defined as having no deletion of RD181,
RD150 or RD142. One sample belonged to sublineage 2
with RD181 deleted but RD150 and RD142 being
present, but the majority of Beijing strains (63/65), in-
cluding all Beijing strains from Alotau, belonged to sub-
lineage 3 with RD180 and RD150 deleted. None of the
samples had a deletion for RD142. Sublineage 3 is usu-
ally rare, hence the high frequency in our sample is sur-
prising. Several studies have shown that sublineage 3 has
rapidly spread in Cape Town, South Africa during the
last decade, probably because of a founder effect and/or
adaptation to the local host-population [39-41]. Due to
the lack of longitudinal data, it is not possible to draw
any conclusion about the time of introduction or the
duration of spread of this subtype in PNG. However, ex-
cept for two outliers, our subtyping data based on RDs
implies a single introduction of the Beijing strain and a
subsequent clonal expansion through PNG. Starting with
this observation, it would be important to follow the
prevalence of this lineage in Madang and in the country
as a whole to monitor a potential increase of Beijing
strains in the future.
The reasons for the observed differences in lineage fre-
quencies in the three study sites surveyed remain specula-
tive. These sites differ in several aspects, e.g. Goroka inTable 2 Univariate and multivariate logistic regressions for th
Explanatory variable Lineage 2
n = 67 (45.58%)
Non-lineage 2





Study site n (%)
Goroka* 23 (34.33) 15 (18.75)
Alotau 27 (40.30) 5 (6.25) 3.5 (1.11
Madang 17 (25.37) 0 (75.00) 0.2 (0.08
Sex, n (%) 31 (46.27) 37 (46.25) 1 (0.52 -
Men* 36 (53.73) 43 (53.75)
Women
Age - median years [IQR] 30 [25-42] 29 [22-40] 1 [0.99 -
HIV status
Negative* 19 (63.33) 44 (95.65) 12.74 (2.5
Positive 11 (36.67) 2 (4.35) 63.07)
TB treatment history, n (%)
No* 55 (91.67) 66 (86.84)
Yes 15 (11.03) 10 (13.16) 0.60 (0.19
Drug resistance (any type)
No* 54 (83.08) 72 (92.31)
Yes 11 (16.92) 6 (7.69) 2.44 (0.85
*reference category.
IQR = interquartile range; OR = odds ratio. A p-value <0.05 was considered statisticathe Highlands had been much longer isolated from the
outside world for much longer than the two coastal sites.
The population in the Highlands are believed to be de-
scendants of the oldest human migration wave that popu-
lated the country [22], however, no statistically significant
difference in the prevalence of Lineage 1 in Goroka could
be detected.
Other factors might also influence the lineage distribu-
tion. Goroka and Madang are connected to the country
through the highlands highway, whilst Madang and Alotau
have direct access to the island of PNG and beyond. Simi-
larly, the host genetic background and environmental or
circumstantial factors such as co-infections or age could
well influence the M. tuberculosis lineage distribution. We
therefore performed univariate and multivariate logistic
regressions to test whether infection with a Lineage 2
strain (equals an infection with Beijing strain) was associ-
ated with other factors such as DR, HIV status, age and
gender (Table 2). Samples not belonging to Lineage 2 were
pooled for the analysis, consisting of five samples of
Lineage 1 and 75 samples of Lineage 4. Univariate logistic
regression confirmed the differences in lineage distribu-
tion between the study sites. These differences remained
significant also when correcting for possible confounders
in a multivariate regression.
Co-infection with HIV has several times been shown










- 11.18) 0.033 3.3 (1.0 - 10.8) 0.047
- 0.43) <0.001 0.2 (0.1 - 0.4) <0.001
1.91) 0.99




- 7.02) 0.097 2.5 (0.7 - 8.5) 0.153
lly significant.
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tween HIV positivity and infection with a Lineage 2
strain (p = 0.002), but due to sample size multivariate lo-
gistic regression could not be performed. However, HIV
prevalence in PNG is still comparably low, in particular
in Alotau (2.1% in Milne Bay Province (Alotau), 5.2% in
Eastern Highlands Province (Goroka) and 2.8% in
Madang Province) [44] and is therefore unlikely to play
a major role in the distribution of lineages.
It is important to note that all differences are between
the frequencies of Lineage 2 and Lineage 4, whilst
Lineage 1 played no major role, although we would have
expected more ancient lineages (Lineage 1) in the high-
lands. Lineage 4 and Lineage 2 are not only the most
prevalent M. tuberculosis lineages in PNG, but are also
predominating globally [3]. Thus, our findings could
support the notion of Hershberg and colleagues [2] that
the lineage distribution between and within countries
might become homogenized with increasing migration.
In other words, more virulent strains such as Lineage 4
and Lineage 2 might slowly replace the ancient lineages
as has already been observed in Cameroon [45] and
might have started in PNG.
Drug resistance
In total 23/212 (10.8%) samples were resistant to at least
one of the drugs tested. The details of the DR patterns
and their frequency in each study site are shown in
Table 3. With 6.6% (14/212) the proportion of isolates
resistant (mono-resistant or poly-resistant) to Strepto-
mycin (STR) was the highest in our cohort. High STR
resistance in PNG is well known and has been found inTable 3 Observed phenotypic drug resistance per study site




INH (0.1 mg/L) 2
INH (0.4 mg/L) 0
RMP 2
Polyresistant 0
STR + INH 0
STR + RMP 0
MDR 1 (1.8)
INH + RMP 0
STR + INH + RMP + EMB 1
STR + INH + RMP 0
STR + INH + RMP + ETH 0
INH + RMP + PZA + ETH 0
GKA = Goroka, ALO = Alotau, MAG =Madang, STR = Streptomycin, INH = Isoniazid, Rprevious studies [18-20]. In the past STR has been used
frequently as single drug to treat TB but also urinary
tract and Klebsiella infections [46] which might have led
to drug resistance. Drug resistance of any type and MDR
frequencies were highest in Alotau with 4.6% of MDR
cases, but monoresistance was observed more often in
Goroka (8.9%) and Madang (6.7%) compared to Alotau
(4.6%). However, none of these differences were statisti-
cally significant (p = 0.960).
In order to determine drug resistance mechanisms of
16 phenotypically drug resistant isolates for which DNA
could be obtained (16/23), we determined mutations in
ten genes known to be associated with resistance. Two
pan-susceptible strains of patients with late sputum con-
version were also included. Sequence data were analysed
and mutations observed are shown in Figure 4.
Streptomycin resistance has been shown to be associated
with mutations in the rrs, rpsL or gidB gene [47,48]. For
two STR mono-resistant samples only a mutation in gidB
was detected (sample 1 in Figure 4) or no mutation was
found in any of the analysed genes, respectively (sample 2
in Figure 4). All observed mutations in that gene had also
been observed in our previous study in Madang. The sole
observation of the synonymous mutation A205G and the
non-synonymous mutation A92C in Lineage 2 strains, sug-
gests that these mutations might be lineage specific [20,49]
with no mutations occurring in Lineage 4. In three sam-
ples, all belonging to Lineage 4, we found the A10P muta-
tion. In contrast to our previous study where the A10P
mutation was absent from 21 pan-susceptible samples, we
observed this mutation in one of the pan-susceptible sam-
ples (sample 17 in Figure 4), probably suggesting that thisALO n = (%) MAG n = (%) TOTAL n = (%)
58 (87.8) 81 (90.0) 189 (89.2)





2 (3.0) 1 (1.1) 3 (1.4)
1 1 2
1 0 1






MP = Rifampicin, EMB = Ethambutol, ETH = Ethionamide, PZA = Pyrazinamide.
Figure 4 Overview of genes/gene regions sequenced and mutations observed. No mutations were found in ahpC, pncA and gyrA. Black
squares: mutation detected at indicated position; white squares: no mutation found at indicated position; dotted squares: no mutation found at
any of the indicated positions, which are the most commonly known sites of mutation for the detected phenotypic drug resistance patterns. All
positions indicate the amino acid change at the codon position, except for rrs gene where nucleotide position and change is indicated.
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mutation V77G found here in one STR resistant strain -
and yet only described from PNG - is involved in STR re-
sistance [20] remains to be determined.
Ninety-five per cent of the rifampicin (RMP) resistance
conferring mutations occur in an 81 bp core region of the
so called rifampin resistance determining region (RRDR)
[50]. We found only one RMP monoresistant sample
(sample 9 in Figure 4) which had no mutation in the
849 bp (including the RRDR) of the rpoB gene we ampli-
fied, confirming that RMP resistant strains without a typ-
ical mutation in the RRDR are not more common in our
sample. This is of crucial importance for the PNG DR sur-
veillance being based on Xpert® MTB/RIF (Cepheid) [51]
which determines RMP resistance only through detection
of mutations in RRDR [52]. However, 26.1% (6/23) of
strains were isoniazid (INH) monoresistant or INH/STR
polyresistant. INH resistance is a precursor to MDR-TB
and is not detected by the Xpert® MTB/RIF, forming an
additional challenge for the control of DR TB that should
be addressed by the NTP in the future.
All low level INH resistant samples (resistant to a con-
centration of 0.1 mg/L INH) of our study showed a mu-
tation in the inhA promoter region, whereas all high
INH resistant samples (0.4 mg/L) showed a mutation at
codon 315 of katG, including all MDR samples and one
of the polyresistant strains with INH and STR resistance
(sample 11 in Figure 4). No mutations were detected in
the ahpC promoter region for any of the samples.
Two MDR samples had no mutation in 850 bp of katG
sequenced, none in the ahpC promoter or the inhA pro-
moter. One of these samples was also resistant toethambutol (EMB) (sample 16 in Figure 4) but had no
mutation in the embB region including codon 306, which
is mutated in up to 68% of clinical EMB resistant strains
[48]. For that sample the whole genome sequence was
available (data not shown) and was used to screen for mu-
tations outside the amplified regions of katG or embB.
Screening revealed a 14 bp deletion at position 2156047 to
2156060 (H37Rv reference, GeneBank AL123456) causing
a truncation of katG through a frameshift, explaining the
phenotypic high INH resistance of that sample. Outside of
the sequenced embB region the non-synonymous muta-
tion G406S was found which had already been described
in several other studies suggesting its role in EMB resist-
ance [53,54]. For the second MDR sample without a katG
mutation, no sequence data was available and the INH re-
sistance conferring mutation could not be determined. It
remains unclear whether a deletion in katG or mutations
in other genes associated with INH resistance, for example
in kasA [50] could be responsible for the INH resistance.
No mutation was found in the amplified regions of
pncA for any of the genotyped isolates. However, since
for the only sample with phenotypic pyrazinamide resist-
ance (Table 3) no DNA could be obtained, genotyping of
that isolate was not possible.
Possible associations with known risk factors for DR
were tested using univariate logistic regressions (Table 4).
Risk of being infected with a DR strain was 5.5 times
higher for patients with a history of TB treatment and
2.4 times higher for patients infected with an Lineage 2
strain although the latter was not statistically significant
(p = 0.097). To correct for possible confounders multi-
variate logistic regression analysis was conducted and
Table 4 Univariate and multivariate logistic regressions for the risk of drug resistance
Explanatory variable Pan-susceptible
n = 189 (89.15%)
Resistant





Crude OR (95% CI) p-value Adj. OR (95% CI) p-value
Study site n (%)
Goroka* 50 (26.46) 6 (26.09)
Alotau 58 (30.69) 8 (34.78) 1.1 (0.4 - 3.5) 0.808
Madang 81 (42.86) 9 (39.13) 0.9 (0.3 - 2.8) 0.890
Sex, n (%)
Men* 92 (48.68) 11 (47.83)
Women 97 (51.32) 12 (52.17) 1.0 (0.4 - 2.5) 0.939
Age - median years [IQR] 29 [24-40] 31 [25-50] 1.0 [1.0 - 1.1] 0.267
HIV status
Negative* 67 (83.75) 11 (78.57)
Positive 13 (16.25) 3 (21.43) 1.4 (0.3 - 5.7) 0.636
TB treatment history, n (%)
No* 155 (92.26) 15 (71.43)
Yes 13 (7.74) 6 (28.57) 5.5 (1.8 - 16.8) 0.003 4.2 (1.1 - 16.7) 0.040
Lineage 2
No* 72 (57.14) 6 (35.29)
Yes 54 (42.86) 11 (64.71) 2.44 (0.85 - 7.02) 0.097 3.4 (1.0 - 11.2) 0.041
*reference category.
IQR = interquartile range; DR = drug resistance; OR = odds ratio.
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with a DR strain with a history of TB treatment de-
creased from 5.5 to 4.2 but remained significant (p =
0.040). This association highlights the importance of
constant access to treatment and compliance for the
control of DR TB. Strengthening the DOTS strategy and
increasing awareness of TB in the population is crucial
also in PNG and needs to be maintained at a high level
in order not to delay diagnosis and to prevent the pos-
sible spread of TB.
Ballif et al. previously found a significant association be-
tween an infection with a Lineage 2 strain and drug resist-
ance in a previous study conducted in Madang (p < 0.010,
OR = 5.2, CI (95%): 1.8 - 15.1) [29]. Also in our current
sample set from Madang a significant association between
Lineage 2 strains and drug resistance was found, but only
after correction for previous TB treatment (p = 0.041, OR =
3.4, CI (95%): 1.0 – 11.2), probably due to the limited sam-
ple size (Table 4). To test whether the two sample sets from
Madang (Ballif et al. versus Madang samples from current
study) differed significantly in the drug resistance data, we
compared the results of the drug resistance and Lineage 2
analyses from both sample sets by a χ2 test of ORs, but no
significant difference was found (χ2 = 0.747).
Because of the small sample size we also only found a
borderline significant association between multiple drug
resistance and Lineage 2 infection (p = 0.058; CI (95%)0.9 – 68.4; OR = 8): there was an 8 times higher risk of
being infected with a polyresistant (resistant to more
than one drug but not MDR) or MDR strain when in-
fected with an Lineage 2 strain compared to an infection
with a strain of a different lineage (in this case Lineage 4
or Lineage 1).Conclusions
The direct comparison of M tuberculosis population
structures from distinct sites in PNG demonstrated
a statistically significant difference between subpopula-
tions. In Madang Lineage 4 was the dominating lineage,
whereas Lineage 2 was more frequently detected in Alo-
tau and Goroka. Although the reasons for the observed
significant differences of the circulating M. tuberculosis
strains between study sites are not yet understood, these
differences might have a major impact on disease and
transmission dynamics in different populations of PNG.
Different control strategies for places with a different M.
tuberculosis lineage composition are not available yet,
i.e. the same control strategies apply for all provinces in
PNG, namely to detect cases and treat them accordingly.
However, by knowing about the increased prevalence of
the Beijing type of M. tuberculosis in Milne Bay Province,
and with the known association between this lineage
and drug resistance, monitoring of the latter should
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come a hot spot for drug resistance and MDR TB.
Our data show that a significant number of drug re-
sistant TB infections are present across the country and
that MDR TB can already be detected in all three sur-
veyed regions of PNG. Nearly all phenotypical resis-
tances were confirmed by sequence analysis.
No inferences can be made from this study for the
whole country because of the small sample size and data
being derived from only three major towns. Nevertheless,
our findings highlight the importance to monitor drug re-
sistance in PNG, and for making it a high priority for the
National TB Control Program.
Methods
Study sites and patient characteristics
The study was conducted in three different sites across
PNG, one site in each region of PNG: in Madang, Madang
Province in the Momase Region; Goroka, Eastern High-
lands Province, in the Highlands Region, and in Alotau,
Milne Bay Province in the Southern Region of PNG. In
Madang, patients were enrolled into the study from
November 2010 onwards. In Goroka, patient enrolment
started in June 2011 and Alotau was added as a study site
in July 2011. In all three study sites enrolment was com-
pleted in July 2012. Three consecutive sputum samples
were collected from adult TB suspect patients (15 years or
older) with chronic productive cough who presented at
any department of the provincial hospitals (Modilon
Hospital, in Madang; Goroka Provincial Hospital in
Goroka; Alotau Provincial Hospital and Gurney Health
Centre in Alotau). Questionnaire based interviews were
conducted to obtain socio-demographic and behavioural
information of each patient. TB was diagnosed by either
direct smear light microscopy (Ziehl-Neelson staining),
fluorescent microscopy (Morse Stain; TB Fluorescent
Stain Kit M, Becton, Dickinson and Company, USA), chest
X-ray, clinical examination or a combination of these
methods. All TB positive study patients were automatically
enrolled into the PNG National TB Program (NTP).
Therefore, patient management, i.e. treatment and follow
up procedures, was carried out according to the NTP
guidelines [51]. For a subset of study patients the HIV sta-
tus could be obtained from the NTP, which recommends
HIV testing of TB positive patients.
Sample processing and drug susceptibility testing
Sputa were obtained from all tuberculosis patients with
pulmonary involvement who were able to produce spu-
tum. Sputum samples were decontaminated according to
Petroff ’s method [55]. Subsequently, these samples were
inoculated into Mycobacterial Growth Indicator Tubes
(BACTEC™ MGIT™ 960 system; BD, Franklin Lakes,
NJ, USA) and sent to the Queensland MycobacteriumReference Lab in Brisbane, Australia, for culture and
drug susceptibility testing (DST). DST utilising the
BACTEC 960 MGIT system was conducted as described
previously [29].
Genotyping of Mycobacterium tuberculosis
DNA was extracted from culture either by InstaGene
Matrix (Bio-Rad, Hercules, CA, USA) following the manu-
facturer’s protocol, with one bacterial colony resuspended
in 1 ml of dH2O as starting material, or by mixing 100 μl
of M. tuberculosis inoculated into Dubos broth (prepared
tubed medium for cultivation of mycobacteria; Becton,
Dickinson and Company, Maryland, USA) with 100 μl dis-
tilled water and subsequent heat killing at 90°C for 1 hour.
The DNA was then used for molecular analyses.
M. tuberculosis isolates were classified into the main
phylogenetic lineages [12] by a TaqMan real-time PCR assay
using single nucleotide polymorphism (SNP) typing [31].
Lineages were further discriminated into families by spoli-
gotyping [56], using a commercial membrane produced by
Ocimum Biosolutions Ltd, India (product IM9702). Infor-
mation on the shared international type (SIT) and the spo-
ligo family were obtained from SITVIT WEB [57]. All
Beijing strains were further sub-classified into monophyletic
groups based on the presence or absence of the regions of
difference (RDs) RD181, RD150 and RD142 as described by
Tsolaki et al. [36]. PCR conditions and primers were used
as previously described by Gagneux et al. [3].
Drug resistance genotyping
Of all phenotypically drug resistant strains for which DNA
could be obtained, drug resistance associated regions of the
following genes were amplified by PCR and sequenced by
Macrogen (The Netherlands): katG, rpoB, ahpC (promoter),
inhA (promoter), gidB, pncA, gyrA, rrs, rpsL, embB. Add-
itionally, two fully susceptible isolates of patients for whom
smear conversion took longer than the usual 2 months
were included. Primers and PCR conditions were used as
previously described by Ballif et al. [20] with the following
modifications; for rpoB a new set of primers was designed:
forward primer 5′AYATCGACCACTTCGGYAACC3′, re-
verse primer 5′TCCTCGATGACGCCGCTTTCT3′ (Y =
C/T). PCR was run with an annealing temperature (TA) of
62°C, an elongation time (ET) of 60 seconds and 37 cycles,
leading to a product length of 849 bp. For the inhA pro-
moter and katG amplification, primers remained the same
as published but the TA was increased from 60°C to 65°C
and the cycle number from 35 to 39 for inhA, and from
64°C to 66°C and from 35 to 40 cycles for katG.
Statistical analysis
Statistical analysis was carried out with Stata 12.1 (Stata-
Corp, College Station, TX, USA). Differences between study
sites were assessed by cross-tabulation and significance
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were considered statistically significant. Univariate logistic
regressions were performed to assess associations of drug
resistance or Lineage 2 infection with known potential pre-
dictors or confounders. Independent variables with a sig-
nificance level of p < 0.2 in the univariate analysis and a
plausible causal link where further analysed in a multivari-
ate logistic regression. Model selection for multivariate re-
gressions was based on the AIC-criterion. The comparison
of two different sample sets from the same study site was
done with a χ2 test of odds ratios with χ2 > 3.84 considered
to show a statistically significant difference (5% level).
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